NOT ACTUAL PATIENT
*SAJAZIR injection is a prefilled syringe for subcutaneous use.1 Patients should not inject SAJAZIR until they have been trained by their healthcare provider or a Cycle Vita™ Clinical Education Manager.
Product
SAJAZIR is an FDA-approved injection indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.1 As you never know when your next hereditary angioedema attack might be, each SAJAZIR single-dose syringe comes pre-filled and ready to go.1
-
- Portable prefilled icatibant injection
- Effective symptom reduction for hereditary angieoadema attacks1
- Used to treat acute hereditary angioedema attacks, including skin (cutaneous) stomach (abdominal), or throat (laryngeal)
- Can be self-administered once you have been trained by a Cycle Vita Clinical Education Manager or your healthcare provider
- Does not require reconstitution/mixing, dose calculation, special handling, dose titration, or refrigeration1
- Taking SAJAZIR as soon as symptoms appear may prevent an attack or reduce its severity1
Support
We understand the importance of providing product support that complements treatment for patients living with a rare disease. That’s why we created Cycle Vita—delivering individualized product support for SAJAZIR. Cycle Vita is here to give you the product support** you need at every step of your journey.
- Continuous clinical support
- 1-to-1 injection training
- Financial assistance, such as Reimbursement Research Support and Co-Pay Assistance Program
- Bridge Program**
**Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.
References
1. SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.